Research paper

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma

Wenliang Tan a,b, Xuan Luo a,b, Wenda Li a,b, Jinyi Zhong b, Jun Cao a,b, Sicong Zhu a,c, Xianqing Chen a,b, Rui Zhou a,b, Changzhen Shang a,b,⁎, Yajin Chen a,b,⁎

a Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
b Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
c Department of Surgical Intensive Care Unit, The Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Abstract

Background: The role of tumor necrosis factor alpha (TNF-α) in targeted therapy for hepatocellular carcinoma (HCC) remains largely unknown. The current study aimed to clarify the mechanistic effects of targeting TNF-α to overcome sorafenib resistance in HCC.

Methods: A correlation of TNF-α expression with the prognosis was analyzed in 62 HCC patients who underwent surgical resection and subsequent received adjuvant sorafenib treatment. The relation of TNF-α expression and sorafenib sensitivity was determined in different HCC cell lines. The combined therapeutic effects of sorafenib and ulinastatin, which could inhibit TNF-α expression, on HCC were examined in vitro and in vivo.

Findings: High TNF-α expression was correlated with poor outcomes in HCC patients who received adjuvant sorafenib after surgery. In vitro experiments showed that TNF-α promotes HCC cell resistant to sorafenib through inducing epithelial-mesenchymal transition (EMT). Notably, the current study revealed that sorafenib has no significant influence on the expression and secretion of TNF-α, and sorafenib had limited effectiveness on reversing EMT in HCC cells with high TNF-α expression. Inhibiting the expression of TNF-α with ulinastatin significantly enhanced the anti-tumor effect of sorafenib on HCC cells with high expression of TNF-α in vitro and in vivo.

Interpretation: Our findings indicate that TNF-α may serve as a novel predictor of sorafenib sensitivity in HCC patients. Sorafenib combined with ulinastatin may improve the effectiveness of treatment of HCC in patients with high expression of TNF-α.

Fund: This work was supported by grants from the National Natural Science Foundation of China (no.81572398; no.81672419), the Science and Technology Planning Project of Guangdong Province (no.2017A010105003; no.2015A050502023; no.2016A020216010), and the Natural Science Foundation of Guangdong Province (no.2014A030313061; no.2013B010100001).

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the digestive system [1]. In recent years, radical treatments such as surgical resection, ablation, and liver transplantation have improved the prognosis of patients with HCC. However, since it is not easy to diagnosis mild damage of liver function [2], most HCC patients are diagnosed at an advanced stage, and they are not candidates for radical treatment. The overall prognosis for HCC is still not optimistic. Sorafenib, a multikinase inhibitor, was the first targeted drug approved for the treatment of advanced HCC [3,4]. Although sorafenib has been proven to improve the prognosis of patients with advanced HCC, drug resistance has resulted in limited survival benefits because of low response rates [5]. As such, it is necessary to clarify the underlying mechanisms associated with sorafenib resistance and identify ways to overcome resistance to improve the anti-tumor effects of sorafenib in HCC.

The concept of inflammation-induced cancer has been established during the past decades, and studies have found that inflammatory factors affect nearly all the stages of tumor development, as well as the effectiveness of therapy [6]. Inflammatory cytokines like interleukin (IL)-1α are considered tumorigenic cytokines, and IL-1α is a promising therapeutic target in advanced colorectal cancer [7]. Elevated levels of IL-6 are associated with poor survival outcomes in many cancers, and recent studies have shown that IL-6 antibody can enhance the anti-tumor effects of chemotherapy or gefitinib in multiple tumor cells [8,9]. Transforming growth factor (TGF)-β, which promotes cell migration...
and vascular invasion and induces angiogenesis, is markedly elevated in a number of different cancers, including HCC. Recent study has also shown that down-regulation of TGF-β enhances the anti-tumor efficacy of epidermal growth factor receptor (EGFR)-targeted therapy [10,11]. Taken together, the results of the aforementioned studies suggest that inflammatory factors may be potential anti-tumor therapeutic targets.

Tumor necrosis factor (TNF)-α is one of the most important inflammatory cytokines, and it was first identified as an anti-tumor cytokine that induced tumor necrosis. Recent evidence has indicated that TNF-α is a central mediator of inflammation, and thus provides a molecular link between chronic inflammation and the development of malignancies [12]. TNF-α is predominantly produced by macrophages, but it is also produced by a variety of tumor cells including gallbladder and kidney cancer and facilitates tumor invasion and metastasis [13,14]. Recent study has also demonstrated that high expression of TNF-α in clear cell renal cell carcinomas was associated with resistance to sunitinib [15]. Study has also shown that TNF-α expression in HCC is significantly higher than that in normal hepatic tissue [16]. However, the role of TNF-α expression with respect to the sensitivity of HCC to sorafenib is unknown. Taken together, these prompt us to explore the exact role of TNF-α in HCC progression and further to investigate its potential role as a therapy target against HCC.

This study examined the association of TNF-α expression and sorafenib resistance in HCC patients. The results indicated that high TNF-α expression was associated with a poorer response to sorafenib. We also demonstrated that sorafenib has no significant influence on TNF-α expression. In addition, our results also showed that inhibiting TNF-α with ulinastatin (UTI) enhanced the effect of sorafenib in HCC cells with high expression of TNF-α through the NF-κB/EMT signaling pathway. Therefore, our study suggests that TNF-α overexpression is a novel mechanism of sorafenib resistance, and inhibition of TNF-α may increase the effectiveness of sorafenib in patients with HCC.

2. Materials and methods

2.1. Cell lines and culture

The human HCC cell lines HepG2, SK-HEP-1, and Huh-7 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Hep3B and PLC/PRF/5 HCC cells were obtained from the American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 100 U/mL penicillin, and 100 U/mL streptomycin, and incubated at 37 °C under an atmosphere containing 5% CO₂.

TNF-α was knockdown by lentiviruses containing short hairpin RNA (shRNA): TNF-α shRNA, 5′-GTAGCCATTTGACGCAA CGTGTCACGT-3′. A scrambled shRNA lentivirus containing a non-targeting sequence (5′-TTTCCGAA CGTGTCACGT-3′, named LV-shNon) was used as a control. The shRNA sequence was synthesized by Shanghai GeneChem Co. Ltd. (Shanghai, China). shRNA were cloned into pLKO.1 (GV248) lentiviral vectors. Culture supernatants containing sh-RNA were added to HCC cells in the presence of polybrene. The cells were selected using 2 μg/mL puromycin after 24 h.

2.2. Reagents and antibodies

Sorafenib (Nexavar®) was purchased from Bayer Pharmaceuticals, and ulinastatin was purchased from Techpool Bio-Pharma (Guangzhou, China). Primary antibody for Snail, Vimentin, E-cadherin, Bcl-2, Bax, and NF-κB (pathway sample kit #9936) were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-TNF-α antibody was purchased from Novus (Littleton, CO, USA), and anti-PCNA antibody was purchased from Abcam (Cambridge, UK). Antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin, and the horse-radish peroxidase (HRP)-labeled anti-rabbit secondary antibodies were from CWBIO (Beijing, China). The human TNF-α ELISA kit was purchased from Abcam.

2.3. Patients and specimens

The clinical data of 62 HCC patients who underwent surgical resection and subsequent received adjuvant sorafenib treatment at Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Guangzhou, China) from January 2007 to June 2014 were collected. Patients were treated with oral sorafenib at a dose of 400 mg twice a day beginning within 30 days after surgery. Patients eligible to receive adjuvant sorafenib after liver resection were those defined as having a high risk of recurrence, including macroscopic vascular invasion (portal vein or branches), microvascular invasion in pathology, or those who were only receiving palliative surgical and locoregional therapies [4]. Tissue specimens were fixed in formalin, and paraffin embedded for immunohistochemical study. The clinical characteristics of the patients included in the study are shown in Supplemental Table S1. The study was approved by the Ethical Committee of Sun Yat-Sen Memorial Hospital. All patients provided written informed consent for all treatment performed and to have their data used for research purposes.

2.4. Immunohistochemical (IHC) analysis

Serial sections of HCC tissue were stained with a 3-step immunoperoxidase method. Sections were deparaffinized with xylene, ethanol, and demineralized water. Antigens were then retrieved by boiling in 1 mM EDTA (pH 8.0) for 10 to 15 min. After the sections were washed in demineralized water and phosphate buffered saline (PBS), the primary antibodies were added and sections were incubated overnight at 4 °C. After washing with PBS, the sections were incubated with EnVision Mouse or Rabbit conjugate (Dako Corporation, Carpenteria, CA, USA) for 60 min at 37 °C. The color reaction was
completed with the DAB-positive substrate. Sections were counterstained with hematoxylin.

The staining results were scored independently by two pathologists in the following manner. The intensity of staining was scored as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The percentage of positive tumor cells was divided into five grades (percentage scores): 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%). The overall score of each sample was determined using the following formula: overall score = intensity score × percentage score. A total score of 0–2, 3–6, 7–9, and 10–12 was defined as negative, weak positive, moderate positive, and strong positive, respectively.

2.5. Western blot

The total protein was extracted from cells lysed with RIPA Lysis Buffer (CWBio) containing protease inhibitors and phosphatase inhibitors (Roche). The protein concentrations of the cell lysates were measured using a bicinchoninic acid assay (Beyotime, Jiangsu, China) and equalized before loading. A total of 30 μg of protein were separated by SDS–PAGE, and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). Immunoblot analyses were carried out using the appropriate antibodies, and the bands were visualized using an enhanced chemiluminescence detection kit (Millipore).

2.6. Cell viability, colony formation, ELISA, apoptosis analyses and cell invasion assays

Cell viability, colony formation, ELISA, apoptosis analyses and cell invasion assays were performed as described in the Supplementary Materials and Methods.

2.7. Immunochemistry assay

HepG2 and SK-HEP-1 cells (2 × 10⁷/well) were seeded in 24-well plates, incubated for 24 h, then treated with TNF-α (40 ng/mL) or ulinastatin (1600 U/mL). Next, HCC cells were washed and fixed with 4% paraformaldehyde (PFA) for 20 min, and permeabilized in 0.3% Triton X-100. Incubation with monoclonal rabbit anti-P65 antibody (CST) overnight at 4 °C was followed by incubation with fluorescein isothiocyanate (Alexa Fluor® 555)-labeled goat anti-rabbit IgG secondary antibody for 60 min in a dark wet box. Following triplicate washes with PBS-T, the cells were counterstained with DAPI (CWBio) for 5 min. The results were photographed under an inverted fluorescence microscope (×400).

2.8. Animal experiments

Female BALB/c athymic nude mice, 4–6 weeks old, were purchased from the Laboratory Animal Center of Sun Yat-Sen University (Guangzhou, China). The mice were maintained in the laboratory for animal experimentation in a specific pathogen-free environment with laminar air-flow conditions, a 12-h light-dark cycle, and at a temperature of 22 °C to 25 °C. All animals had free access to standard laboratory mouse food and water. Animal experiments were approved by the Bioethics Committee of Sun Yat-Sen University and were performed according to the established guidelines.

2.9. Xenograft tumor growth

A total of 5 × 10⁶ SK-HEP-1 cells were suspended in 200 μL serum-free DMEM and injected into the right flanks of the mice. The mice were then randomized into three groups (n = 6/group): vehicle control...
(ddH2O, orally), sorafenib (30 mg/kg/d, orally), and sorafenib (30 mg/kg/d, orally) combined with UTI (20,000 U twice a week, IP).

Once palpable tumors were observed, measurements of tumor volume were taken every 3 days using calipers. The tumor volume was calculated using the following formula: \( V = (l \times w^2) \times 0.5 \), where \( l \) and \( w \) refer to the larger and smaller dimensions collected at each measurement. The mice were killed after 2 weeks' treatment, and the solid tumors were excised, weighed, and fixed in formaldehyde.

### 2.10. In vivo metastasis analysis

SK-HEP-1 cells (1 \( \times 10^6/0.2 \) mL) were injected into 4–6 weeks old female nude mice by way of tail vein to imitate tumor metastasis. Experimental animals (\( n = 6 \) group) were divided into four groups: vehicle control (ddH2O, orally), sorafenib (30 mg/kg/d, orally), UTI (20,000 U twice a week, IP), and sorafenib (30 mg/kg/d, orally) combined with UTI (20,000 U twice a week, IP). The mice were sacrificed after 4 weeks of treatment, and their livers and lungs were weighed and sampled for tissue sectioning.

### 2.11. Statistical analysis

Data were reported as mean ± standard deviations, and compared using Student’s \( t \)-test and two-way analysis of variance (ANOVA) with Bonferroni correction. A value of \( p < 0.05 \) was considered to indicate statistical significance.

### 3. Results

#### 3.1. High expression of TNF-\( \alpha \) is correlated with poor prognosis in HCC

In order to test the expression of TNF-\( \alpha \) and explore its expression with the prognosis in HCC patients, we collected the tissues of 62 HCC patients who received adjuvant sorafenib treatment after surgical resection. In our cohort, 61.3% (38/62) had a high level of TNF-\( \alpha \) expression (Supplemental Table S1). Statistical analysis showed that high expression of TNF-\( \alpha \) in HCC tissue was positively associated with multiple clinical pathological features including TNM stage (\( p < 0.05 \)), BCLC stage (\( p < 0.05 \)), and histological grade (\( p < 0.05 \)) (Supplemental Table S2).
The multivariate Cox regression analysis indicated that TNF-α was not an independent risk factor of overall survival (OS) after surgical resection (hazard ratio [HR] 0.898; 95% confidence interval [CI]: 0.413–1.955; P = .787), but the results demonstrated that TNF-α was an independent risk factor of recurrence free survival (RFS) after surgical resection (hazard ratio [HR] 2.487; 95% confidence interval [CI]: 1.146–5.396; P = .021 (Table S3 and S4). Furthermore, the Kaplan-Meier analysis showed that high expression of TNF-α was correlated with poorer overall survival and higher recurrence rates (Fig. 1b, c). Taken together, the results suggested that overexpression of TNF-α was correlated with poor prognosis in HCC. We also detected the expression level of TNF-α in five HCC cell lines by western blot and ELISA. The results revealed that SK-HEP-1 exhibited higher expression of TNF-α, while the TNF-α expression in HepG2 cells was much lower (Fig. 1d, e).

3.2. TNF-α promotes sorafenib resistance by inducing epithelial-mesenchymal transition (EMT) in HCC cells

To investigate the biological characteristics of TNF-α in HCC cells, we used a specific shRNA to knock down TNF-α expression in SK-HEP-1 (named SK-HEP-1-shTNF-α; supplemental Fig. 1a, b), and we added 40 ng/mL of TNF-α to stimulate HepG2 cell. The results showed that TNF-α stimulation could promote HCC cells proliferative and migratory ability, whereas down-regulated TNF-α in SK-HEP-1 cells significantly reduced the proliferation and migration of HCC cells. Moreover, its proliferation and migration abilities were rescued when we added extrinsic TNF-α to the SK-HEP-1-shTNF-α (Supplemental Fig. 1c-g). To determine the role of TNF-α in mediating sorafenib resistance in HCC, we treated HCC cells with different doses of sorafenib for 48 h. The IC50 values of the HepG2 and SK-HEP-1 cells were 6.20 μmol/L and 12.83 μmol/L, respectively. However, the IC50 values of the HepG2 cells pretreated with TNF-α was 8.12 μmol/L, and the IC50 values for the SK-HEP-1-shTNF-α cells were 7.32 μmol/L (Fig. 2a, b). Furthermore, the proliferation assay showed that sorafenib at the dose of 6 μmol/L could dramatically inhibit the growth of HepG2 cells, but the inhibition efficiency decreased a lot when HepG2 cells pretreated with TNF-α stimulation. However, sorafenib (6 μmol/L) only showed mild inhibition on the growth of SK-HEP-1 cells, whereas it markedly suppressed the proliferation ability in SK-HEP-1-shTNF-α cells (Fig. 2c).

Previous studies have implied an association between EMT and sorafenib resistance [17], and a wide range of evidence has suggested that TNF-α can induce EMT in different cancer cells [18,19]. Our results also demonstrated that TNF-α induced a typical change of EMT markers (up-regulation of snail and vimentin, and down-regulation of E-cadherin) in HCC cells (Fig. 2d). We explored the effect of sorafenib on EMT, and we found that sorafenib decreased snail and vimentin, and elevated E-cadherin in HepG2 cells. However, when TNF-α was pre-added to HepG2 cells, the effect of sorafenib on reversing EMT was decreased. Notably, our results showed that sorafenib almost had no effect on EMT in SK-HEP-1 cells with or without the presence of TNF-α (Fig. 2e). Furthermore, when HCC cells were treated with 3, 6, and 12 μmol/L concentrations of sorafenib, we found that sorafenib nearly had no influence on TNF-α expression in both the HCC cell lines (Fig. 2f).

3.3. Ulinastatin suppresses EMT of HCC cells through inhibiting TNF-α expression and secretion

Ulinastatin is widely used for the treatment of inflammatory-related diseases. Previous studies have showed that ulinastatin inhibits the production of TNF-α in macrophages and breast cancer cells [20,21]. In the current study, HCC cells were cultivated with ulinastatin at various concentrations (200, 400, 800, 1600, and 3200 U/mL) for 48 h. Western blot results showed that ulinastatin down-regulated TNF-α expression...
in a dose-dependent manner (Fig. 3a). Detection of TNF-α by ELISA showed that 800 and 1600 U/mL of ulinastatin markedly decreased the TNF-α level in HCC cell supernatants, while sorafenib at the concentrations of 6 and 12 μmol/L almost had no effect on TNF-α secretion (Fig. 3c). We further examined the effect of ulinastatin on reversing the EMT of HCC cells. The results showed that when the concentration of ulinastatin exceeded 1600 U/mL, the epithelial marker E-cadherin was significantly up-regulated, and the mesenchymal markers (snail and vimentin) were markedly down-regulated in both the two HCC cell lines (Fig. 3b). Furthermore, when we used a concentration of 1600 U/mL of ulinastatin to down-regulated TNF-α in HepG2 and SK-HEP-1 cells, western blot results indicated that sorafenib markedly inhibited the EMT in both the two HCC cell lines (Fig. 3d).

3.4. Ulinastatin enhances the anti-tumor effect of sorafenib in HCC cells

Since we showed that down-regulation of TNF-α by ulinastatin promoted sorafenib inhibition of EMT in HCC cells, we speculated that down-regulating TNF-α by ulinastatin might improve the effect of sorafenib against HCC cells, especially for the HCC cells with high expression of TNF-α. In the colony formation assay, sorafenib (6 μmol/L) alone could inhibit the proliferation of SK-HEP-1 cells to 55.79% compared with the control, while ulinastatin (1600 U/mL) alone could only mildly inhibit the proliferation of SK-HEP-1 cells. The effect of the two drugs combined was superior to the effect of either drug alone (Fig. 4a). Similar results were also found in the cell apoptotic ratio measured by flow cytometry (Fig. 4b), and western blot to detect PCNA (a proliferation-related protein), Bcl-2 (an anti-apoptotic protein), and Bax (an apoptosis-related protein) expression (Fig. 4c), where sorafenib treatment alone was superior to ulinastatin, and combination treatment was superior to either drug alone. We demonstrated the combination of sorafenib and ulinastatin could more effectively inhibit HCC cell proliferation and induce cell apoptosis than sorafenib or ulinastatin alone. Results of the wound healing assay indicated that the combination of sorafenib and ulinastatin significantly suppressed cell migration compared to sorafenib or ulinastatin alone in SK-HEP-1 cells (Fig. 4d).
Moreover, the Transwell assay also revealed the combination of sorafenib and ulinastatin more significantly inhibited cell migration and invasion (Fig. 4e). In addition, we also detected the effect of combined therapy on HepG2 cells, and the results showed that sorafenib markedly suppressed the progression of HepG2 cells, while co-treatment with sorafenib and ulinastatin had better efficacy (Supplemental Fig. 2).

3.5. Combined treatment with sorafenib and ulinastatin exerts a more potent anti-tumor effect against HCC in vivo

To confirm the synergistic effect of sorafenib and ulinastatin in vivo, xenograft tumor models were prepared with SK-HEP-1 cells. Compared with the groups treated with sorafenib or control, tumor growth in the group treated with combined therapy of sorafenib and ulinastatin was significantly inhibited (Fig. 5a, b). Meanwhile, the tumor weight in sorafenib alone group was 61.94% to that of the control group, while tumor weight in the co-treatment group was 32.35% to that of the control group at the end of the study (Fig. 5c). To examine the effect of combined sorafenib and ulinastatin against metastasis in vivo, SK-HEP-1 cells were injected into nude mice by way of tail vein to imitate tumor metastasis. Metastases in the lung and liver reduced to 56.47% and 54.07%, respectively, in the sorafenib group. However, when using the co-treatment of ulinastatin with sorafenib, the metastases in the lung and liver reduced to 16.40% and 25.58%, respectively, compared with control group (Fig. 5d, e).

3.6. Ulinastatin inhibits HCC cell invasion and proliferation via regulating the NF-κB/EMT signaling pathway

We further explored the signaling mechanisms of ulinastatin for its effect on TNF-α inhibition. Firstly, we observed P65 nuclear translocation using immunofluorescence staining, and we found that exogenous TNF-α markedly induced P65 nuclear translocation, while ulinastatin prevented P65 nuclear translocation (Fig. 6a, b). Then, we investigated the effect of sorafenib and ulinastatin on activation of the NF-κB signaling pathway. As shown in Fig. 6c, ulinastatin alone remarkably decreased the phosphorylation of IKK-β, IκB, and P65, while sorafenib had a limited inhibition effect on the NF-κB pathway in HCC cells. Moreover, co-treatment with the two drugs had a superior effect than that of either drug alone. Second, to determine whether inhibition of the NF-κB pathway in HCC cells has an anti-tumor effect, we treated the two HCC cell lines with BAY11–7082 (an inhibitor...
specifically inhibit P65 translating to the nuclear) to inhibit NF-κB activity. Western blot results showed that inhibiting the NF-κB pathway significantly reversed EMT (Supplemental Fig. 3b) and inhibited the mobility of HCC cells (Supplemental Fig. 3a). We also observed that co-treatment with sorafenib and BAY 11–7082 demonstrated superior effect than either drug alone for the growth inhibition of HCC cells. More importantly, our results revealed that the inhibition efficiency of the combined therapy nearly showed no difference with or without the presence of TNF-α (Fig. 6d). Similar results also found in the cell migration and invasion measured by Transwell migration assay (Fig. 6e and supplemental Fig. 3c).

Tumor sections of the subcutaneous tumors in the SK-HEP-1 cell models were stained for TNF-α, P65, vimentin, and Ki67. The results showed that co-treatment with sorafenib and ulinastatin significantly suppressed the expression of TNF-α, vimentin, and Ki67, and the nuclear translocation of P65. Interestingly, the results demonstrated that sorafenib alone had a limited effect on TNF-α and vimentin expression, and it could not prevent the nuclear translocation of P65 (Fig. 7a, b). Taken together, these results indicated that ulinastatin could inhibit the TNF-α/NF-κB signaling pathway, and thus enhanced the anti-tumor effect of sorafenib in HCC.

4. Discussion

In the present study, we demonstrated that the expression of TNF-α is positively correlated with the therapeutic response to sorafenib in
HCC patients. For the first time we found that sorafenib could not reduce the expression and secretion of TNF-α. We also demonstrated that ulinastatin, a urinary protease inhibitor widely used in the treatment of inflammatory diseases, markedly enhanced the effect of sorafenib on suppressing the progression of HCC in vitro and in vivo.

Sorafenib is currently the only molecular targeted drug approved for advanced HCC patients. However, the response rate is unsatisfactory because of drug resistance. A recent examination of two phase 3 studies, the SHARP trial and ORIENTAL trial, found that inflammation is an indicator of a poor prognosis after sorafenib treatment in patients with HCC [22]. Other study has showed that a high baseline HBV load was an independent predictor of poor survival, and co-administration of antiviral therapy with sorafenib reduced the viral load and improved overall survival in HCC patients [23]. The above studies indicate that inhibiting the inflammatory reaction may be an effective adjuvant therapy in HCC patients.

Inflammatory factors affect nearly all the stages of tumor development, as well as the effectiveness of therapy. TNF-α is one of the most important inflammatory mediators of the cancer-associated inflammatory networks. Preclinical studies in breast cancer and pancreatic cancer have suggested that TNF-α promotes tumor growth in vivo and that anti-TNF-α treatments may suppress tumor progression [24,25]. Previous studies also showed that the serum TNF-α level in in patients with cirrhosis and HCC is significantly higher than that in healthy individuals, and high expression of TNF-α is positively associated with high-grade tumors and predicts poor survival in HCC patients [26,27]. Our results
demonstrated that TNF-α was positively related with the proliferation and invasion ability of HCC cells, which is consistent with the results of previous studies of HCC and other tumors. However, the current study is the first to demonstrate that the expression of TNF-α is positively related to sorafenib resistance in HCC cells. We systematically showed that sorafenib could significantly inhibit the EMT in HepG2 cells (with low expression of TNF-α), but only slightly affect the EMT in HCC cells with high expression of TNF-α (SK-HEP-1 cells). Moreover, when exogenous TNF-α was added to HepG2 cells, the inhibition of EMT by sorafenib was dramatically impaired. Importantly, we found that sorafenib could not reduce the expression and secretion of TNF-α. Together, these results demonstrated that sorafenib has a limited effect on inhibiting the TNF-α-induced EMT in HCC cells.

Compelling evidence from recent investigations has highlighted the notion that EMT is an important mechanism of sorafenib resistance in advanced HCC [28,29]. The effect of sorafenib on inhibiting EMT has been reported previously, and it has been proven that sorafenib exerts a potent inhibitory effect against HGF mediated-EMT and TGF-β mediated-EMT in HCC cells [30,31]. However, the effect of sorafenib on reversing EMT in HCC cells with different TNF-α expression levels has not been reported. Our results revealed that sorafenib does not inhibit the EMT of HCC cells through regulating TNF-α expression, but possibly via other mechanisms (HGF or TGF-β). The NF-κB signaling pathway has been shown to play an important role in promoting inflammatory reactions, and functions as an essential mediator of EMT [32]. However, the effect of sorafenib on the NF-κB signaling pathway in HCC cells remains controversial. It has been reported that sorafenib effectively inhibits the activation of the NF-κB signaling pathway induced by radiotherapy in HCC, thereby enhancing the effect of radiotherapy [33]. However, another study showed that sustained sorafenib stimulation could activate NF-κB activity, thus induced HCC cell resistance to sorafenib [34]. Our results demonstrated that sorafenib had limited effect on inhibiting the NF-κB pathway in HCC cells, and this finding is consistent with a study by Osama et al. [35]. It is known that TNF-α is an activator of the NF-κB signaling pathway, and our results showed that sorafenib did not reduce the expression and secretion of TNF-α in the HCC cells. This might be the reason for the limited effect of sorafenib on the NF-κB/EMT signaling pathway in HCC cells.

Our study also showed that TNF-α plays an important role in HCC resistance to sorafenib. This promoted us to explore whether inhibiting TNF-α could overcome sorafenib resistance in HCC cells. Previous research has demonstrated that lenalidomide, an immune modulatory drug that could inhibit TNF-α expression, enhances the anti-tumor effect of sorafenib in HCC cells [36]. However, a phase I clinical trial found that the combination of lenalidomide and sorafenib was poorly tolerated because of toxicity side effects [37]. Therefore, exploring an anti-TNF-α drug with low toxicity side effect might benefit those HCC patients with high expression of TNF-α. Here we demonstrated that ulinastatin, which was widely used in clinic for the treatment of inflammatory-related diseases, could suppress the expression of TNF-α in HCC cells. Recent studies have reported that ulinastatin has therapeutic effects against several cancer types, including breast cancer, malignant mesothelioma, and colorectal cancer [38–40], but its role in HCC was unclear now. In the current study, we found that ulinastatin combined with sorafenib exerted a more significant anti-tumor effect in HCC cells with high expression of TNF-α in vitro and in vivo. Its mechanism might through suppressing the TNF-α/NF-κB/EMT signaling pathway. Other study have demonstrated that ulinastatin could down-regulate the expression of TNF-α, IL-6 and IL8 in breast cancer [20]. In this study, we mainly focused on the correlation of TNF-α and sorafenib sensibility in HCC, and we demonstrated that ulinastatin could suppress the expression of TNF-α. Therefore, it was worthwhile to explore other inflammatory cytokines like IL-6 or IL-8 might also participate in the mechanism of ulinastatin against HCC.

Taken together, our study results suggest that targeting TNF-α may overcome HCC resistance to sorafenib. We demonstrated that ulinastatin enhanced the anti-tumor effect of sorafenib against HCC by inhibiting the TNF-α/NF-κB/EMT signaling pathway. Further studies examining the effect of TNF-α suppression therapy on the outcomes of sorafenib treatment for HCC are warranted.

Acknowledgements and funding sources

This work was supported by grants from the National Natural Science Foundation of China (no. 81572398; no. 81672419), the Science and Technology Planning Project of Guangdong Province (no. 2017A010105003; no. 2015A050502023; no. 2016A020216010), the Natural Science Foundation of Guangdong Province (no. 2014A030313061; no. 2013B021800101). These funding sources had no role in the study design, data collection, data analysis, interpretation, or writing of this manuscript.

Declaration of interests

The authors declare that they have no competing interests.

Author contributions

Yajin Chen and Changzhen Shang designed the experiments; Wenliang Tan performed the experiments and wrote the manuscript; Xuan Luo and Jun Cao collected the clinical samples; Wenda Li and Jinji Zhong analyzed and made interpretation of the data. Sicong Zhu made up pictures and graphs. Xiaoqing Chen and Rui Zhou revised the manuscript; All the authors read and approved the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.12.047.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7–30.
[2] Qi X, Berzigotti A, Cardenas A, Sarin S. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol 2018;3(10):708–19.
[3] Liu L, Cao Y, Chen C, Zhang X, McNabola A, Willkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24):11831–8.
[4] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Cane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90.
[5] Villanueva A, Llovet JM. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clinical Cancer Research 2012;18(7):1824-6.
[6] Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clinc Oncol 2015;12(10):584-96.
[7] Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocjić J, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 2017;18(2):192–201.
[8] Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012;47(4):570-84.
[9] Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, et al. A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Cancer Res 2016;76(2):480–90.
[10] Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ, et al. Inhibition of TGF-beta enhances the in vivo antitumor effi cacy of EGFR-targeted therapy. Mol Cancer Ther 2012;11(11):2429–39.
[11] Arjaans M, Oude Munnik TH, Timmer-Roschka H, Reiss M, Walenkamp AM, Lubs-de Hooge MN, et al. Transforming growth factor (TGF)-beta expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. Pharmacol Ther 2012;135(2):123–32.
[12] Brunner D, Blauer H, Mak TW. Regulation of tumour necrosis factor signaling; live or let die. Nat Rev Immunol 2015;15(6):362–74.
[13] Zhu C, Du Q, Wang X, Tang N, She F, Chen Y. TNF-alpha promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. Int J Mol Med 2014;33(6):1431–40.
[14] Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, et al. Tumor-derived tumour necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99(5):905–13.

W. Tan et al. / EBioMedicine 40 (2019) 446–456

455
[15] Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y. Expression of TNF-alpha and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 2015;136(7):1504–14.

[16] Liu XL, Li FQ, Liu LX, Li B, Zhou ZP. TNF-alpha, HGF and macrophage in peritumoral liver tissue relate to major risk factors of HCC Recurrence. Hepatogastroenterology 2013;60(125):1121–4.

[17] Mir N, Jayachandran A, Dhungel B, Shrestha R, Steel JC. Epithelial-to-Mesenchymal transition: a Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma. Curr Cancer Drug Targets 2017;17(8):698–706.

[18] Wang H, Fang R, Wang XF, Zhang F, Chen DY, Zhou B, et al. Stabilization of Snail through AKT/GSK-3beta signaling pathway is required for TNF-alpha-induced epithelial-mesenchymal transition in prostate cancer PC3 cells. Eur J Pharmacol 2013;714(1–3):48–55.

[19] Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu J, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 2012;72(5):1290–300.

[20] Zhao X, Sun X, Gao F, Luo J, Sun Z. Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-alpha. Journal of Exp Clin Cancer Res 2011;30(1):22.

[21] Molor-Erdene P, Okajima K, Irobe H, Uchiba M, Harada N, Okabe H. Urinary trypsin inhibitor inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-alpha production through inhibition of Egr-1 expression. Am J Physiol Heart Circ Physiol 2005;288(3):H1265–71.

[22] Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017;67(5):999–1008.

[23] Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015;35(5):1838–405.

[24] Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, et al. Anti-tumor necrosis factor-alpha suppresses breast cancer growth. Cancer Res 2013;73(13):4061–74.

[25] Yu M, Zhou X, Niu L, Lin G, Huang J, Zhou W, et al. Targeting transmembrane TNF-alpha suppresses breast cancer growth. Cancer Res 2013;73(13):4061–74.

[26] Liu ZC, Ning F, Wang HF, Cai YN, Sheng HY, et al. Epidermal growth factor and tumor necrosis factor alpha cooperatively promote the motility of hepatocellular carcinoma cell lines via synergistic induction of fibronectin by NF-kappaB/p65. Biochim Biophys Acta 2017;1861(11 Pt A):2568–82.

[27] Wang H, Liu J, Hu X, Liu S, He B. Prognostic and Therapeutic Values of Tumor Necrosis Factor-alpha in Hepatocellular Carcinoma. Med Sci Monit 2016;22:3694–704.